# Yuhan Corporation clinical trials: 110 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 110 trials with Yuhan Corporation as lead sponsor, 7 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Yuhan Corporation: 110 rows for $5.50, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/yuhan-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 110
- Recruiting or not yet: 7
- Read on: November 19, 2026

## Trials

The 25 newest of 110, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07912840 | Bioequivalence Study Between YHP2508B and YHR2602 in Healthy Subjects | Yuhan Corporation | Phase 1 | Recruiting | Healthy Subjects (HS) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912840) |
| November 3, 2026 | NCT07912827 | Bioequivalence Study Between YHP2508A and YHR2601 in Healthy Subjects | Yuhan Corporation | Phase 1 | Recruiting | Healthy Subjects (HS) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912827) |
| May 13, 2026 | NCT07584304 | Bioequivalence Study Between YHP2508C and YHR2603 in Healthy Subjects | Yuhan Corporation | Phase 1 | Completed | Healthy Subjects | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584304) |
| March 13, 2026 | NCT07470125 | Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers | Yuhan Corporation | Phase 1 | Completed | Healthy Subjects | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07470125) |
| February 17, 2026 | NCT07415551 | Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines | Yuhan Corporation | Phase 2 | Recruiting | Allergic Diseases, Chronic Spontaneous Urticaria (CSU) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07415551) |
| December 4, 2025 | NCT07265167 | Bioequivalence Study Between YHP2406 and YHR2501 in Healthy Subjects | Yuhan Corporation | Phase 1 | Completed | Healthy Subjects | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07265167) |
| August 8, 2025 | NCT07111468 | Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis | Yuhan Corporation | Phase 3 | Completed | Acute Bronchitis | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07111468) |
| May 16, 2025 | NCT06975410 | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors | Yuhan Corporation | Phase 1/2 | Recruiting | EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06975410) |
| April 13, 2025 | NCT06926387 | Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy Subjects | Yuhan Corporation | Phase 1 | Completed | Healthy Volunteer | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926387) |
| April 10, 2025 | NCT06920719 | Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects | Yuhan Corporation | Phase 1 | Completed | Healthy Subject | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06920719) |
| January 15, 2025 | NCT06775522 | Bioequivalence (BE) Study Between YHP2205 and YHR2401 in Healthy Volunteers | Yuhan Corporation | Phase 1 | Completed | Healthy Volunteers | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06775522) |
| October 3, 2024 | NCT06625957 | Clinical Trial to Evaluate the Safety and Efficacy of NTCB02-1 in Patients Who Require Parenteral Nutrition | Yuhan Corporation | Phase 3 | Recruiting | Parenteral Nutrition | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06625957) |
| October 3, 2024 | NCT06625931 | Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition | Yuhan Corporation | Phase 3 | Completed | Parenteral Nutrition | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06625931) |
| October 2, 2024 | NCT06623526 | Clinical Trial to Evaluate the PK Interactions of YHR2402 Monotherapy and YHR2402 and YHR2403 Co-Administration in Healthy Volunteers | Yuhan Corporation | Phase 1 | Completed | Healthy Volunteers | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06623526) |
| September 27, 2024 | NCT06616766 | A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 | Yuhan Corporation | Phase 1/2 | Recruiting | NSCLC (Non-small Cell Lung Cancer), Solid Tumor | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06616766) |
| September 25, 2024 | NCT06613139 | Bioequivalence Study Between YHP2305 and YHR2404 in Healthy Volunteers | Yuhan Corporation | Phase 1 | Completed | Healthy Volunteers | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06613139) |
| July 24, 2024 | NCT06517914 | A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants | Yuhan Corporation | Phase 1 | Active not recruiting | Healthy Participants | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06517914) |
| April 11, 2024 | NCT06359626 | Bioequivalence Study Between YHP2205 and YHR2401 in Healthy Volunteers | Yuhan Corporation | Phase 1 | Completed | Healthy Volunteers | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06359626) |
| March 5, 2024 | NCT06293261 | Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in... | Yuhan Corporation | Observational | Completed | Hypertension, Hypercholesterolemia | 5,047 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06293261) |
| February 28, 2024 | NCT06282549 | Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension | Yuhan Corporation | Observational | Active not recruiting | Essential Hypertension | 1,219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06282549) |
| February 7, 2024 | NCT06247280 | Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation | Yuhan Corporation | Observational | Active not recruiting | NSCLC | 2,001 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06247280) |
| September 21, 2023 | NCT06046196 | Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease | Yuhan Corporation | Phase 4 | Completed | Arterial Occlusive Diseases, Intermittent Claudication | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06046196) |
| September 18, 2023 | NCT06041529 | Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension | Yuhan Corporation | Phase 4 | Active not recruiting | Essential Hypertension | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06041529) |
| July 27, 2023 | NCT05960708 | A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases | Yuhan Corporation | Phase 1 | Completed | Allergic Disease, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05960708) |
| May 17, 2023 | NCT05862194 | Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC | Yuhan Corporation | Observational | Completed | Non-small Cell Lung Cancer | 534 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05862194) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 50 |
| Phase 1/2 | 8 |
| Phase 2 | 12 |
| Phase 3 | 11 |
| Phase 4 | 21 |
| Not applicable | 2 |
| Observational | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 90 |
| Recruiting | 7 |
| Active not recruiting | 4 |
| Unknown | 4 |
| Terminated | 4 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertension | 16 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Hyperlipidemias | 7 |
| Diabetes Mellitus, Type 2 | 6 |
| Dyslipidemias | 5 |
| Hypercholesterolemia | 3 |
| Acute Coronary Syndrome | 3 |
| Chronic Urticaria | 2 |
| Bronchitis | 2 |
| Diabetes Mellitus | 2 |
| Intervertebral Disc Degeneration | 2 |
| Biliary Tract Neoplasms | 2 |
| Atherosclerosis | 2 |
| Chronic Periodontitis | 2 |
| Hyperphagia | 2 |
| Peripheral Arterial Disease | 2 |
| Essential Hypertension | 2 |
| Chronic Inducible Urticaria | 1 |
| Cold Urticaria | 1 |
| Breast Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Esophagitis, Peptic | 1 |
| Renal Insufficiency, Chronic | 1 |
| Proteinuria | 1 |
| Thrombocythemia, Essential | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Wine wholesalers in the United States](https://specstream.ai/data/businesses/wine-wholesalers/united-states)
- [Abrasives suppliers in the United States](https://specstream.ai/data/businesses/abrasives-suppliers/united-states)
- [Aesthetic medicine clinics in the United States](https://specstream.ai/data/businesses/aesthetic-medicine-clinics/united-states)
- [Air duct cleaning companies in the United States](https://specstream.ai/data/businesses/air-duct-cleaning-companies/united-states)
- [Aluminum suppliers in the United States](https://specstream.ai/data/businesses/aluminum-suppliers/united-states)
- [Apparel manufacturers in the United States](https://specstream.ai/data/businesses/apparel-manufacturers/united-states)
